Baker Avenue Asset Management LP Takes $1.22 Million Position in Illumina, Inc. (ILMN)

Baker Avenue Asset Management LP bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, HoldingsChannel.com reports. The fund bought 5,581 shares of the life sciences company’s stock, valued at approximately $1,219,000.

Several other institutional investors have also modified their holdings of ILMN. Financial Gravity Companies Inc. acquired a new stake in Illumina during the fourth quarter valued at $106,000. Dupont Capital Management Corp acquired a new stake in Illumina during the third quarter valued at $153,000. SeaCrest Wealth Management LLC acquired a new stake in Illumina during the fourth quarter valued at $154,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after purchasing an additional 410 shares during the last quarter. Finally, Patten Group Inc. boosted its position in Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after purchasing an additional 615 shares during the last quarter. 90.65% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Illumina, Inc. (ILMN) opened at $250.12 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. The company has a market capitalization of $36,770.00, a PE ratio of 42.11, a PEG ratio of 3.31 and a beta of 0.93. Illumina, Inc. has a 12 month low of $158.02 and a 12 month high of $250.67.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.85 earnings per share. research analysts predict that Illumina, Inc. will post 4.59 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday. Deutsche Bank set a $275.00 target price on Illumina and gave the company a “buy” rating in a report on Tuesday, January 16th. Cowen raised their target price on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, January 22nd. Leerink Swann raised their target price on Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Morgan Stanley raised their target price on Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the stock. Illumina has a consensus rating of “Buy” and an average target price of $241.39.

In other news, Director Frances Arnold sold 250 shares of Illumina stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $241.50, for a total value of $60,375.00. Following the transaction, the director now directly owns 10,439 shares in the company, valued at $2,521,018.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $224.50, for a total value of $32,552.50. Following the completion of the transaction, the senior vice president now owns 7,411 shares in the company, valued at $1,663,769.50. The disclosure for this sale can be found here. Insiders sold 72,887 shares of company stock worth $16,510,025 over the last quarter. 0.89% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/03/12/baker-avenue-asset-management-lp-takes-1-22-million-position-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply